Diabetes Dialogue: Addressing Health Disparities with Diabetes Technology, with Etty Vider, PharmD

Earlier this month, the Association of Diabetes Care and Education Specialists (ADCES) celebrated the organization’s 50th anniversary through their 2023 annual meeting (ADCES 23).

Hosted in-person from August 3-7, 2023, in Houston, TX and on-demand from August 21-October 30, 2023, the meeting featured nearly 200 unique presentations and hundreds of leading experts from across the continuum of the diabetes care team. Among these experts was Etty Vider, PharmD, of ambulatory care clinical pharmacist at Zing Health, which is a physician-founded and led provider of Medicare Advantage health plans

During her time at ADCES 2023, Vider led a presentation titled “Address Health Disparities with a CGM Remote Patient Monitoring Program”. During this session, Vider reviewed barriers to technology utilization in underserved populations as well as practical strategies to overcome these barriers and increase technology use. Vider also described the implementation of a continuous glucose monitor remote patient monitoring program for participants enrolled in a Medicare Advantage Plan led by clinical pharmacists and how this program addressed health disparities.

As part of our celebration of the 50th anniversary of the ADCES and ADCES 23, Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, have recorded multiple special edition episodes with guests and presenters from the meeting, including Vider.

During this episode, hosts Isaacs and Bellini are joined by Vider for a nuanced discussion surrounding leveraging diabetes technology to improve care for people with diabetes. In their conversation with Vider, Isaacs and Bellini explore strategies for improving utilization of diabetes technology, the role of primary care in adoption of these technologies, and outcomes from the aforementioned pharmacist-led program.

Relevant disclosures for Dr. Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.